1. Home
  2. GEOS vs DMAC Comparison

GEOS vs DMAC Comparison

Compare GEOS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geospace Technologies Corporation (Texas)

GEOS

Geospace Technologies Corporation (Texas)

HOLD

Current Price

$17.47

Market Cap

199.6M

Sector

Industrials

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.21

Market Cap

441.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEOS
DMAC
Founded
1980
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.6M
441.6M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
GEOS
DMAC
Price
$17.47
$8.21
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
220.5K
470.5K
Earning Date
02-04-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$110,803,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$3.19
52 Week High
$29.89
$10.42

Technical Indicators

Market Signals
Indicator
GEOS
DMAC
Relative Strength Index (RSI) 51.88 48.81
Support Level $15.84 $8.16
Resistance Level $18.70 $8.73
Average True Range (ATR) 1.28 0.61
MACD 0.61 -0.14
Stochastic Oscillator 67.11 7.23

Price Performance

Historical Comparison
GEOS
DMAC

About GEOS Geospace Technologies Corporation (Texas)

Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: